Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Isoleucine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.43 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 11/20 | 0.43 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.43 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.39 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Isoleucine SCHEMBL1537377 | 1.00 | SLC7A5 (0.46) | SLC7A5GLRA1SLC6A9OR51E2DPP4 | |
| Isoleucine SCHEMBL1537379 | 1.00 | SLC7A5 (0.46) | SLC7A5GLRA1SLC6A9OR51E2DPP4 | |
| Isoleucine SCHEMBL4400069 | 1.00 | SLC7A5 (0.46) | SLC7A5GLRA1SLC6A9OR51E2DPP4 | |
| Isoleucine SCHEMBL8492488 | 1.00 | SLC7A5 (0.46) | SLC7A5GLRA1SLC6A9OR51E2DPP4 | |
| Isoleucine SCHEMBL3046356 | 1.00 | SLC7A5 (0.46) | SLC7A5GLRA1SLC6A9OR51E2DPP4 | |
| Isoleucine SCHEMBL1537299 | 1.00 | SLC7A5 (0.46) | SLC7A5GLRA1SLC6A9OR51E2DPP4 | |
| Isoleucine SCHEMBL1675494 | 1.00 | SLC7A5 (0.46) | SLC7A5GLRA1SLC6A9OR51E2DPP4 | |
| Isoleucine SCHEMBL11168084 | 0.96 | SLC7A5 (0.43) | SLC7A5GLRA1SLC6A9OR51E2DPP4 | |
| Isoleucine SCHEMBL3057441 | 0.96 | SLC7A5 (0.43) | SLC7A5GLRA1SLC6A9OR51E2DPP4 | |
| Isoleucine SCHEMBL2547350 | 0.96 | SLC7A5 (0.43) | SLC7A5GLRA1SLC6A9OR51E2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024140670-A1 | CONJUGATE AND USES THEREOF | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2024-07-04 | — | — | WO | claimed |
| US-11384117-B2 | Connective tissue stimulating peptides | OCTANE ORTHOBIOLOGICS INC. (CA) | 2022-07-12 | — | — | US | claimed |
| WO-2021062231-A2 | CANNABINOID PRODRUG COMPOUNDS | FIRSTLIGHT PHARMACEUTICALS LLC (US) | 2021-04-01 | — | — | WO | claimed |
| US-20190077831-A1 | CONNECTIVE TISSUE STIMULATING PEPTIDES | MILLENIUM BIOLOGIX INC. (CA) | 2019-03-14 | — | — | US | claimed |
| US-10202419-B2 | Connective tissue stimulating peptides | OCTANE ORTHOBIOLOGICS INC. (CA) | 2019-02-12 | — | — | US | claimed |
| EP-3423569-A1 | 3D PRINTING OF A CELLULARISED SCAFFOLD | Oxford University Innovation Limited (GB) | 2019-01-09 | — | — | EP | claimed |
| CN-107311943-A | It is a kind of to promote Cyclic dipeptides of angiogenesis and preparation method thereof | 四川好医生攀西药业有限责任公司 | 2017-11-03 | — | — | CN | claimed |
| EP-3074415-A1 | NOVEL ULTRASHORT HYDROPHOBIC PEPTIDES THAT SELF-ASSEMBLE INTO NANOFIBROUS HYDROGELS AND THEIR USES | Agency For Science, Technology And Research (SG) | 2016-10-05 | — | — | EP | claimed |
| US-20160237117-A1 | CONNECTIVE TISSUE STIMULATING PEPTIDES | MILLENIUM BIOLOGIX INC. (CA) | 2016-08-18 | — | — | US | claimed |
| WO-2015080670-A1 | NOVEL ULTRASHORT HYDROPHOBIC PEPTIDES THAT SELF-ASSEMBLE INTO NANOFIBROUS HYDROGELS AND THEIR USES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-06-04 | — | — | WO | claimed |
| US-20120156276-A1 | Connective tissue stimulating peptides | MILLENIUM BIOLOGIX INC. (CA) | 2012-06-21 | — | — | US | claimed |
| US-20050288229-A1 | Connective Tissue Stimulating Peptides | MILLENIUM BIOLOGIX INC. (CA) | 2005-12-29 | — | — | US | claimed |
| EP-1504033-A2 | CONNECTIVE TISSUE STIMULATING PEPTIDES | MILLENIUM BIOLOGIX INC. (CA) | 2005-02-09 | — | — | EP | claimed |
| WO-2003093314-A2 | CONNECTIVE TISSUE STIMULATING PEPTIDES | MILLENIUM BIOLOGIX INC. (CA) | 2003-11-13 | — | — | WO | claimed |
| US-4340592-A | OLICOPEPTIDES FOR DIETARY PURPOSES | ADIBI SIAMAK A | 1982-07-20 | — | — | US | claimed |
| WO-2024140670-A1 | CONJUGATE AND USES THEREOF | FULL-LIFE TECHNOLOGIES HK LIMITED (CN) | 2024-07-04 | — | — | WO | disclosed |
| US-11980602-B2 | Cannabinoid prodrug compounds | FIRSTLIGHT PHARMACEUTICALS LLC (US) | 2024-05-14 | — | — | US | disclosed |
| US-4263293-A | ANTIARTHRITIC AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1981-04-21 | — | — | US | disclosed |
| EP-0021766-A2 | Inhibitors of mammalian collagenase | E.R. Squibb & Sons, Inc. (US) | 1981-01-07 | — | — | EP | disclosed |
| US-4235885-A | Inhibitors of mammalian collagenase | E. R. SQUIBB & SONS, INC. (US) | 1980-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11980602-B2 | Cannabinoid prodrug compounds | CNR2, CNR1, FAAH | SLC7A5 4029/4885GLRA1 2621/4885SLC6A9 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.